Quadrant Capital Group LLC Exelixis, Inc. Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 6,011 shares of EXEL stock, worth $210,685. This represents 0.01% of its overall portfolio holdings.

Number of Shares

6,011

Previous 5,810 3.46%

Holding current value

$210,685

Previous $130,000 19.23%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$21.96 - $27.6 $4,413 - $5,547	201 Added 3.46%	6,011 $155,000
Q2 2024 Aug 12, 2024	SELL	$20.34 - $23.73 $17,736 - $20,692	-872 Reduced 13.05%	5,810 $130,000
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $20,714 - $24,576	-1,027 Reduced 13.32%	6,682 $158,000
Q4 2023 Feb 08, 2024	BUY	$19.25 - $24.13 $14,437 - $18,097	750 Added 10.78%	7,709 $184,000
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $3,731 - $4,457	196 Added 2.9%	6,959 $152,000
Q2 2023 Aug 09, 2023	BUY	$18.17 - $20.48 $3,415 - $3,850	188 Added 2.86%	6,763 $129,000
Q1 2023 May 11, 2023	BUY	$16.3 - $19.41 $63,211 - $75,271	3,878 Added 143.79%	6,575 $127,000
Q4 2022 Feb 10, 2023	BUY	$14.96 - $17.39 $22,754 - $26,450	1,521 Added 129.34%	2,697 $43,000
Q3 2022 Nov 10, 2022	BUY	$15.68 - $22.27 $5,221 - $7,415	333 Added 39.5%	1,176 $18,000
Q2 2022 Aug 09, 2022	SELL	$17.44 - $23.16 $6,941 - $9,217	-398 Reduced 32.07%	843 $18,000
Q1 2022 May 06, 2022	BUY	$17.03 - $22.67 $8,872 - $11,811	521 Added 72.36%	1,241 $28,000
Q4 2021 Feb 01, 2022	SELL	$15.84 - $21.88 $2,217 - $3,063	-140 Reduced 16.28%	720 $13,000
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $1,352 - $1,754	-83 Reduced 8.8%	860 $18,000
Q2 2021 Aug 09, 2021	SELL	$17.95 - $25.56 $10,159 - $14,466	-566 Reduced 37.51%	943 $17,000
Q1 2021 May 12, 2021	BUY	$20.53 - $25.22 $3,141 - $3,858	153 Added 11.28%	1,509 $34,000
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $4,156 - $5,604	-226 Reduced 14.29%	1,356 $27,000
Q3 2020 Nov 13, 2020	BUY	$20.67 - $26.94 $1,178 - $1,535	57 Added 3.74%	1,582 $39,000
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $7,917 - $13,189	481 Added 46.07%	1,525 $36,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $5,075 - $7,651	-351 Reduced 25.16%	1,044 $18,000
Q4 2019 Feb 03, 2020	SELL	$15.15 - $18.89 $26,845 - $33,473	-1,772 Reduced 55.95%	1,395 $24,000
Q3 2019 Oct 24, 2019	BUY	$17.68 - $22.65 $28,712 - $36,783	1,624 Added 105.25%	3,167 $54,000
Q2 2019 Jul 24, 2019	SELL	$18.93 - $24.75 $7,818 - $10,221	-413 Reduced 21.11%	1,543 $30,000
Q1 2019 Apr 29, 2019	BUY	$19.6 - $24.76 $5,703 - $7,205	291 Added 17.48%	1,956 $42,000
Q4 2018 Jan 17, 2019	BUY	$13.65 - $21.8 $3,330 - $5,319	244 Added 17.17%	1,665 $30,000
Q3 2018 Oct 29, 2018	BUY	$15.87 - $22.4 $2,634 - $3,718	166 Added 13.23%	1,421 $23,000
Q2 2018 Aug 09, 2018	SELL	$18.56 - $22.45 $501 - $606	-27 Reduced 2.11%	1,255 $27,000
Q3 2017 Oct 13, 2017	BUY	$23.35 - $29.24 $630 - $789	27 Added 2.15%	1,282 $30,000
Q2 2017 Aug 15, 2017	BUY	N/A	1,255	1,255 $30,000

Others Institutions Holding EXEL

# of Institutions

495

Shares Held

244M

Call Options Held

2.4M

Put Options Held

2.21M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Exelixis, Inc. Transaction History